CompletedNCT04030169
MDMA-Assisted Therapy for PTSD: Feasibility and Brain Imaging
About this title
Read the official source — NCT04030169Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Klecany and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 24, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 21
- Sponsor
- MAPS Europe B.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Czechia, Germany, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT04030169
- Official title
Show the full official title
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Psychotherapy With an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects With Posttraumatic Stress Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Klecany, Czechia · Berlin, Germany · Oegstgeest, Netherlands
4 more locations
- Moss, Norway
- Cardiff, United Kingdom
- London, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is MAPS Europe B.V.
Did this study involve medication?
Yes. The study involved medication, including Midomafetamine HCl.
Who was this study for?
Listed age limits: from 18 years.
